From somatic mutations to Quotient
We spoke to Dr Iñigo Martincorena, group leader at the Wellcome Sanger Institute and academic co-founder of Quotient Therapeutics. Quotient is a new company leveraging Sanger Institute research to innovate the way drugs are discovered.